{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:44:16Z","timestamp":1793015056647,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn201909199"],"award-info":[{"award-number":["tsqn201909199"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202306403"],"award-info":[{"award-number":["tsqn202306403"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["GES13507"],"award-info":[{"award-number":["GES13507"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["GSE135337"],"award-info":[{"award-number":["GSE135337"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH241"],"award-info":[{"award-number":["ZR2023MH241"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH271"],"award-info":[{"award-number":["ZR2023QH271"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073131"],"award-info":[{"award-number":["82073131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303813"],"award-info":[{"award-number":["82303813"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370690"],"award-info":[{"award-number":["82370690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.arcmed.2023.102927","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T18:06:35Z","timestamp":1703700395000},"page":"102927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy"],"prefix":"10.1016","volume":"55","author":[{"given":"Tianqi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanshan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2023.102927_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2023.102927_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0003","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2023.102927_bib0004","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0005","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.arcmed.2023.102927_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","article-title":"Targeting the microenvironment in solid tumors","volume":"65","author":"Belli","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.arcmed.2023.102927_bib0007","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature03096","article-title":"Stromal fibroblasts in cancer initiation and progression","volume":"432","author":"Bhowmick","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2023.102927_bib0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41585-022-00608-y","article-title":"The dynamic roles of the bladder tumour microenvironment","volume":"19","author":"Lee","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0009","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.arcmed.2023.102927_bib0010","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccell.2020.09.004","article-title":"Immunometabolic Interplay in the Tumor Microenvironment","volume":"39","author":"Kaymak","year":"2021","journal-title":"Cancer cell"},{"key":"10.1016\/j.arcmed.2023.102927_bib0011","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arcmed.2023.102927_bib0012","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arcmed.2023.102927_bib0013","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0092-8674(00)81731-6","article-title":"Tumor induction of VEGF promoter activity in stromal cells","volume":"94","author":"Fukumura","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2023.102927_bib0014","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","article-title":"The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance","volume":"2","author":"Fearon","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.arcmed.2023.102927_bib0015","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1242\/jcs.00094","article-title":"Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation","volume":"115","author":"Sun","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.arcmed.2023.102927_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0955-0674(99)00080-0","article-title":"The genetics of the protein 4.1 family: organizers of the membrane and cytoskeleton","volume":"12","author":"Hoover","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00418-014-1224-z","article-title":"Comprehensive characterization of protein 4.1 expression in epithelium of large intestine","volume":"142","author":"Zhang","year":"2014","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0018","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1083\/jcb.201111127","article-title":"The cytoskeletal adapter protein 4.1G organizes the internodes in peripheral myelinated nerves","volume":"196","author":"Ivanovic","year":"2012","journal-title":"J Cell Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0019","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1128\/MCB.05945-11","article-title":"Essential function of protein 4.1G in targeting of membrane protein palmitoylated 6 into Schmidt-Lanterman incisures in myelinated nerves","volume":"32","author":"Terada","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0020","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1074\/jbc.M115.658591","article-title":"Protein 4.1G Regulates Cell Adhesion, Spreading, and Migration of Mouse Embryonic Fibroblasts through the \u03b21 Integrin Pathway","volume":"291","author":"Chen","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2023.102927_bib0021","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/mol.119.116426","article-title":"Activity of Adenylyl Cyclase Type 6 Is Suppressed by Direct Binding of the Cytoskeletal Protein 4.1G","volume":"96","author":"Saito","year":"2019","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0022","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.cellsig.2012.11.020","article-title":"Suppression of adenylyl cyclase-mediated cAMP production by plasma membrane associated cytoskeletal protein 4.1G","volume":"25","author":"Goto","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.arcmed.2023.102927_bib0023","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbrc.2012.08.129","article-title":"Band 4.1 proteins regulate integrin-dependent cell spreading","volume":"426","author":"Jung","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.arcmed.2023.102927_bib0024","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.12659\/MSM.914085","article-title":"Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies","volume":"25","author":"Feng","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.arcmed.2023.102927_bib0025","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.3390\/ijms20112750","article-title":"Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan","volume":"20","author":"Menyh\u00e1rt","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2023.102927_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-9-3","article-title":"Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer","volume":"9","author":"Kim","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.arcmed.2023.102927_bib0027","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/ijc.33794","article-title":"Single-cell RNA sequencing reveals the epithelial cell heterogeneity and invasive subpopulation in human bladder cancer","volume":"149","author":"Lai","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2023.102927_bib0028","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.arcmed.2023.102927_bib0029","doi-asserted-by":"crossref","first-page":"D956","DOI":"10.1093\/nar\/gkx1090","article-title":"LinkedOmics: analyzing multi-omics data within and across 32 cancer types","volume":"46","author":"Vasaikar","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.arcmed.2023.102927_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.arcmed.2023.102927_bib0031","first-page":"1739","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.arcmed.2023.102927_bib0032","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell systems"},{"key":"10.1016\/j.arcmed.2023.102927_bib0033","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0034","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0035","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2023.102927_bib0036","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.arcmed.2023.102927_bib0037","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0038","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0039","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41585-019-0226-y","article-title":"The multifaceted immune regulation of bladder cancer","volume":"16","author":"Schneider","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.arcmed.2023.102927_bib0041","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2023.102927_bib0042","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0043","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.arcmed.2023.102927_bib0044","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2022.03.014","article-title":"Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy","volume":"86","author":"Gaikwad","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13046-019-1110-6","article-title":"Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology","volume":"38","author":"Nissen","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2023.102927_bib0046","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.semcancer.2005.05.003","article-title":"Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression","volume":"15","author":"Beacham","year":"2005","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0047","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arcmed.2023.102927_bib0048","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.4049\/jimmunol.1402520","article-title":"Fibroblastic reticular cells: organization and regulation of the T lymphocyte life cycle","volume":"194","author":"Brown","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109422","article-title":"Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts","volume":"36","author":"Rodriguez","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.arcmed.2023.102927_bib0050","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41590-019-0515-x","article-title":"Fibroblastic reticular cells enhance T cell metabolism and survival via epigenetic remodeling","volume":"20","author":"Brown","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0051","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and Function of the PD-L1 Checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.arcmed.2023.102927_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004569","article-title":"NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer","volume":"10","author":"Yan","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.arcmed.2023.102927_bib0053","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1002\/ctm2.718","article-title":"BRD4-IRF1 axis regulates chemoradiotherapy-induced PD-L1 expression and immune evasion in non-small cell lung cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.arcmed.2023.102927_bib0054","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.arcmed.2023.102927_bib0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.arcmed.2023.102927_bib0056","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0057","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41568-021-00336-2","article-title":"Genetic and non-genetic clonal diversity in cancer evolution","volume":"21","author":"Black","year":"2021","journal-title":"Nature reviews Cancer"},{"key":"10.1016\/j.arcmed.2023.102927_bib0058","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/cas.12745","article-title":"FGF-1\/-3\/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7","volume":"106","author":"Bai","year":"2015","journal-title":"Cancer science"},{"key":"10.1016\/j.arcmed.2023.102927_bib0059","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?(\u2020)","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.arcmed.2023.102927_bib0060","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","article-title":"FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440923001650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:53:18Z","timestamp":1759261998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440923001650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0188440923001650"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102927","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of EPB41L2 in Cancer-Associated Fibroblasts: Prognostic Implications for Bladder Cancer and Response to Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2023.102927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102927"}}